Accéder au contenu
Merck

Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions.

ACS chemical biology (2012-04-20)
Xianbin Yang, Malgorzata Sierant, Magdalena Janicka, Lukasz Peczek, Carlos Martinez, Tom Hassell, Na Li, Xin Li, Tianzhi Wang, Barbara Nawrot
RÉSUMÉ

Chemically synthesized small interfering RNAs (siRNAs) have been widely used to identify gene function and hold great potential in providing a new class of therapeutics. Chemical modifications are desired for therapeutic applications to improve siRNA efficacy. Appropriately protected ribonucleoside-3'-yl S-[β-(benzoylmercapto)ethyl]pyrrolidino-thiophosphoramidite monomers were prepared for the synthesis of siRNA containing phosphorodithioate (PS2) substitutions in which the two non-bridging oxygen atoms are replaced by sulfur atoms. A series of siRNAs containing PS2 substitutions have been strategically designed, synthesized, and evaluated for their gene silencing activities. These PS2-siRNA duplexes exhibit an A-form helical structure similar to unmodified siRNA. The effect of PS2 substitutions on gene silencing activity is position-dependent, with certain PS2-siRNAs showing activity significantly higher than that of unmodified siRNA. The relative gene silencing activities of siRNAs containing either PS2 or phosphoromonothioate (PS) linkages at identical positions are variable and depend on the sites of modification. 5'-Phosphorylation of PS2-siRNAs has little or no effect on gene silencing activity. Incorporation of PS2 substitutions into siRNA duplexes increases their serum stability. These results offer preliminary evidence of the potential value of PS2-modified siRNAs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tris(1-pyrrolidinyl)phosphine, 97%